Abstract
Peroxisome proliferator-activated receptor (PPAR) γ is expressed in human colon cancer, prostate cancer and breast cancer cells, and PPARγ activation induces growth inhibition in these cells. PPARγ expression in human gastric cancer cells, however, has not been fully investigated. We report the PPARγ expression in human gastric cancer, and the effect of PPARγ ligands on proliferation of gastric carcinoma cell lines. Immunohistochemistry was used to demonstrate the presence of PPARγ protein in surgically resected specimens from well differentiated, moderately differentiated and poorly differentiated adenocarcinoma. We used reverse transcription-polymerase chain reaction and Northern and Western blot analyses to demonstrate PPARγ expression in four human gastric cancer cell lines. PPARγ agonists (troglitazone and 15-deoxy-Δ12,14-prostaglandin J2) showed dose-dependent inhibitory effects on the proliferation of the gastric cancer cells, and their effect was augmented by the simultaneous addition of 9-cisretinoic acid, a ligand of RXRα. Flow cytometry demonstrated G1 cell cycle arrest and a significant increase of annexin V-positive cells after treatment with troglitazone. These results suggest that induction of apoptosis together with G1 cell cycle arrest may be one of the mechanisms of the antiproliferative effect of PPARγ activation in human gastric cancer cells. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Asou H, Verbeek W, Williamson E, Elstner E, Kubota T, Kamada N and Koeffler HP (1999) Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int J Oncol 15: 1027–1031
Bishop-Bailey D and Hla T (1999) Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2. J Biol Chem 24: 17042–17048
Brockman JA, Gupta RA and Dubois RN (1998) Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115: 1049–1055
Chawla A, Schwarz EJ, Dimaculangan DD and Lazar MA (1994) Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135: 798–800
Clay CE, Namen AW, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA and Chilton FH (1999) Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 20: 1905–1911
Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks RN, Campbell N, Spiegelman BM and Singer S (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96: 3951–3956
Elstner E, Muller C, Koshizuka K, Asou H, Williamson EA, Park D, Shintaku P, Said JW, Heber D and Koeffler HP (1998) Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95: 8806–8811
Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM and Evans RM (1995) 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte differentiation factor PPARγ. Cell 83: 803–812
Hirase N, Yanase T, Mu YM, Muta K, Umemura T, Takayanagi R and Nawata H (1999) Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology 57(Suppl 2): 17–25
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ and Wang ZY (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567–572
Hu E, Tontonoz P and Spiegelman BM (1995) Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPa. Proc Natl Acad Sci USA 92: 9856–9860
Keelan JA, Sato TA, Marvin KW, Lander J, Gilmour RS and Mitchell MD (1999) 15-Dexoy-Δ12,14-prostaglandin J2, a ligand for peroxisome proliferator-activated receptor γ, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun 262: 579–585
Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S and Mastuzawa Y (1999) Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancers. Jpn J Cancer Res 90: 75–80
Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC and Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83: 813–819
Kubota T, Koshizuka K, Asou H, Williamson EA, Said JW, Holded S, Miyoshi I and Koeffler HP (1998) Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344–3352
Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R and Auwerx J (1998) Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCmin/+mice. Nat Med 4: 1053–1057
Lehmann JM, Lenhard JM, Oliver BB, Ringold GM and Kliewer SA (1997) Peroxisome proliferator-activated receptor α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406–3410
Mukherjee R, Davles PJA, Cromble DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paternitl JRJR and Heyman RA (1997) Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386: 407–410
Pelton PD, Zhou L, Demarest KT and Burris TP (1999) PPARγ activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem Biophys Res Commun 261: 456–458
Saez E, Tontonoz P, Nelson MC, Alvarez JGA, Ming U-T, Baird SM, Thomazy VA and Evans RM (1998) Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 4: 1058–1061
Sarraf P, Mueller E, Jones D, King FJ, Deangelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C and Spiegelman BM (1998) Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 4: 1046–1052
Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamoto K, Sakurada Y, Ui M and Tokumitsu Y (1999) Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21 Waf1/Cip1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 261: 833–837
Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I and Kohgo Y (1999) Activation of PPARγ inhibits cell growth and apoptosis in human gastric cancer cells. FEBS Lett 455: 135–139
Tontonoz P, Hu E and Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPARγ 2, a lipid-activated transcription factor. Cell 79: 1147–1156
Tontonoz P, Singer S, Forman AM, Sarraf P, Fletcher JA, Fletcher CDM, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM and Spiegelman BM (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci USA 94: 237–241
Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA and Evans RM (1998) PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241–252
Warrell RP, Frankel SR, Miller WHJR, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS and Dmitrovsky E (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324: 1385–1393
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sato, H., Ishihara, S., Kawashima, K. et al. Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists. Br J Cancer 83, 1394–1400 (2000). https://doi.org/10.1054/bjoc.2000.1457
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1457
Keywords
This article is cited by
-
A novel metabolism-related prognostic gene development and validation in gastric cancer
Clinical and Translational Oncology (2022)
-
Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical WNT/beta‐catenin pathway
Clinical and Translational Medicine (2017)
-
Quantitative targeted metabolomics for 15d-deoxy-Δ12, 14-PGJ2 (15d-PGJ2) by MALDI-MS
Biotechnology and Bioprocess Engineering (2017)
-
Theoretical studies on the reactivity of thiazole derivatives
Monatshefte für Chemie - Chemical Monthly (2014)
-
DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma
BMC Research Notes (2012)